Why the study?
Despite prophylactic measures, many conventional chemotherapeutic agents cause acute and chronic kidney injury, making understanding their onconephrotoxic profiles essential to optimize treatment and minimize kidney complications.
Do platinum-based and antimetabolite chemotherapeutic agents cause acute and chronic kidney injury in patients with cancer?
Do platinum-based and antimetabolite chemotherapeutic agents cause acute and chronic kidney injury in patients with cancer?
Understanding the nephrotoxic profiles of platinum compounds and antimetabolite agents is essential for optimizing anticancer treatment while minimizing kidney complications.
Anticancer therapies have significantly improved survival rates in patients with cancer; however, despite prophylactic measures, many conventional chemotherapeutic agents cause acute and chronic kidney injury. This review provides a comprehensive analysis of the incidence, characteristics and management of platinum-based and antimetabolite chemotherapeutic agent-associated nephrotoxicity based on the existing literature. Understanding the profiles of these onconephrotoxic agents is essential for optimizing anticancer treatment while minimizing kidney complications.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: